Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Meropenem,Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : SciClone Pharmaceuticals
Deal Size : $113.0 million
Deal Type : Licensing Agreement
Details : Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue...
Product Name : Vaborem
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : Meropenem,Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : SciClone Pharmaceuticals
Deal Size : $113.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Meropenem,Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the deal, Hikma will responsible for the registration and commercialization of Orbactiv and Vabomere across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Ba...
Product Name : Vabomere
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 29, 2021
Lead Product(s) : Meropenem,Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Vaborbactam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2014
Lead Product(s) : Vaborbactam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vaborbactam
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 25, 2013
Lead Product(s) : Vaborbactam
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2013
Lead Product(s) : Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2013
Lead Product(s) : Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2012
Lead Product(s) : Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable